Hoe Pharma Of Malaysia Seeks European Joint Ventures
This article was originally published in PharmAsia News
Executive Summary
Malaysia's Hoe Pharma Holdings says it is seeking joint ventures with European counterparts to enhance its presence in the European market. Hoe CEO B.K. Lee said his firm, a dermatological product specialist, is looking for ties with a European pharmaceutical companies that would hold majority interest there and a corresponding venture in Malaysia in which Hoe would hold majority interest. He said he hopes to sign such a deal next year, giving Hoe a new range of products to market. A unit of Goldis, Hoe specializes in over-the-counter products and ethical drugs, mainly prescription-based. (Click here for more
You may also be interested in...
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.